Stories
Heart Valve Disease: TAVR, MitraClip Revolutionize Treatment, Minimizing Open-Heart Surgery
F
Firstpost•28-09-2026, 06:00
Heart Valve Disease: TAVR, MitraClip Revolutionize Treatment, Minimizing Open-Heart Surgery
- •Advances in structural heart care, like TAVR and MitraClip, are transforming heart valve disease treatment, offering catheter-based alternatives to open-heart surgery.
- •These minimally invasive procedures expand options for older patients, those with multiple medical conditions, or high surgical risk, reducing recovery times.
- •TAVR treats severe aortic stenosis by replacing the valve via a catheter, while MitraClip repairs leaking mitral valves by bringing leaflets closer together.
- •The COAPT and PARTNER 3 trials demonstrate the effectiveness of these procedures, with TAVR showing comparable outcomes to surgery for low-risk patients.
- •Future developments focus on personalized treatment and multidisciplinary approaches, though open-heart surgery remains vital for certain cases.
Key Questions Answered
TAVR is a minimally invasive procedure where doctors guide a replacement valve through a thin catheter, typically inserted via an artery in the groin, to position it inside the stiff, diseased aortic valve without opening the chest or performing thoracic surgery.
MitraClip is a catheter-delivered device used for selected patients with significant mitral regurgitation that brings the valve leaflets closer together to reduce backward blood flow.
No, catheter-based procedures do not replace surgery for every patient. Treatment suitability depends on factors such as the type and severity of valve disease, patient anatomy, age, overall health, and surgical risk determined through a multidisciplinary heart team.
